Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia.
In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.
The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico.
The company was founded in 2007 and is headquartered in Miami, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | 0.01 Increased by +111.11% | -0.10 Increased by +110.00% |
| Nov 7, 24 | -0.03 Increased by +72.73% | -0.09 Increased by +66.67% |
| Aug 7, 24 | -0.01 Increased by +66.67% | -0.09 Increased by +88.89% |
| May 7, 24 | -0.12 Decreased by -500.00% | -0.09 Decreased by -33.33% |
| Feb 27, 24 | -0.09 Increased by +18.18% | -0.09 |
| Nov 6, 23 | -0.11 Increased by 0.00% | -0.10 Decreased by -10.00% |
| Aug 3, 23 | -0.03 Increased by +78.57% | -0.07 Increased by +57.14% |
| May 3, 23 | -0.02 Increased by +75.00% | -0.08 Increased by +75.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 183.64 M Increased by +0.96% | 14.03 M Increased by +121.09% | Increased by +7.64% Increased by +120.89% |
| Sep 30, 24 | 173.63 M Decreased by -2.78% | 24.89 M Increased by +129.46% | Increased by +14.33% Increased by +130.30% |
| Jun 30, 24 | 182.19 M Decreased by -31.36% | -10.30 M Increased by +47.53% | Decreased by -5.66% Increased by +23.56% |
| Mar 31, 24 | 173.69 M Decreased by -26.90% | -81.84 M Decreased by -349.65% | Decreased by -47.12% Decreased by -515.11% |
| Dec 31, 23 | 181.90 M Decreased by -1.89% | -66.51 M Increased by +21.94% | Decreased by -36.56% Increased by +20.44% |
| Sep 30, 23 | 178.60 M Decreased by -0.64% | -84.50 M Increased by +1.80% | Decreased by -47.31% Increased by +1.17% |
| Jun 30, 23 | 265.42 M Decreased by -14.35% | -19.64 M Increased by +80.68% | Decreased by -7.40% Increased by +77.44% |
| Mar 31, 23 | 237.60 M Decreased by -27.83% | -18.20 M Increased by +67.14% | Decreased by -7.66% Increased by +54.47% |